Literature DB >> 20150743

The Gene-Environment Interactions in Respiratory Diseases (GEIRD) Project.

R de Marco1, S Accordini, L Antonicelli, V Bellia, M D Bettin, C Bombieri, F Bonifazi, M Bugiani, A Carosso, L Casali, L Cazzoletti, I Cerveri, A G Corsico, M Ferrari, A G Fois, V Lo Cascio, A Marcon, A Marinoni, M Olivieri, L Perbellini, P Pignatti, P Pirina, A Poli, G Rolla, E Trabetti, G Verlato, S Villani, M E Zanolin.   

Abstract

The role of genetic and environmental factors, as well as their interaction, in the natural history of asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD) is largely unknown. This is mainly due to the lack of large-scale analytical epidemiological/genetic studies aimed at investigating these 3 respiratory conditions simultaneously. The GEIRD project is a collaborative initiative designed to collect information on biomarkers of inflammation and oxidative stress, individual and ecological exposures, diet, early-life factors, smoking habits, genetic traits and medication use in large and accurately defined series of asthma, allergic rhinitis and COPD phenotypes. It is a population-based multicase-control design, where cases and controls are identified through a 2-stage screening process (postal questionnaire and clinical examination) in pre-existing cohorts or new samples of subjects. It is aimed at elucidating the role that modifiable and genetic factors play in the occurrence, persistence, severity and control of inflammatory airway diseases, by way of the establishment of a historical multicentre standardized databank of phenotypes, contributed by and openly available to international epidemiologists. Researchers conducting population-based surveys with standardized methods may contribute to the public-domain case-control database, and use the resulting increased power to answer their own scientific questions. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20150743     DOI: 10.1159/000283034

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  22 in total

1.  The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population.

Authors:  Roberto de Marco; Giancarlo Pesce; Alessandro Marcon; Simone Accordini; Leonardo Antonicelli; Massimiliano Bugiani; Lucio Casali; Marcello Ferrari; Gabriele Nicolini; Maria Grazia Panico; Pietro Pirina; Maria Elisabetta Zanolin; Isa Cerveri; Giuseppe Verlato
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

2.  Seventy Years of Asthma in Italy: Age, Period and Cohort Effects on Incidence and Remission of Self-Reported Asthma from 1940 to 2010.

Authors:  Giancarlo Pesce; Francesca Locatelli; Isa Cerveri; Massimiliano Bugiani; Pietro Pirina; Ane Johannessen; Simone Accordini; Maria Elisabetta Zanolin; Giuseppe Verlato; Roberto de Marco
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

3.  The impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations and limitations in daily activities: a population-based observational study.

Authors:  Simone Accordini; Angelo Guido Corsico; Lucia Calciano; Roberto Bono; Isa Cerveri; Alessandro Fois; Pietro Pirina; Roberta Tassinari; Giuseppe Verlato; Roberto de Marco
Journal:  BMC Pulm Med       Date:  2015-02-12       Impact factor: 3.317

4.  Socioeconomic inequalities in smoking habits are still increasing in Italy.

Authors:  Giuseppe Verlato; Simone Accordini; Giang Nguyen; Pierpaolo Marchetti; Lucia Cazzoletti; Marcello Ferrari; Leonardo Antonicelli; Francesco Attena; Valeria Bellisario; Roberto Bono; Lamberto Briziarelli; Lucio Casali; Angelo Guido Corsico; Alessandro Fois; MariaGrazia Panico; Pavilio Piccioni; Pietro Pirina; Simona Villani; Gabriele Nicolini; Roberto de Marco
Journal:  BMC Public Health       Date:  2014-08-27       Impact factor: 3.295

5.  Nrf2 expression is increased in peripheral blood mononuclear cells derived from mild-moderate ex-smoker COPD patients with persistent oxidative stress.

Authors:  Anna Maria Fratta Pasini; Marcello Ferrari; Chiara Stranieri; Paola Vallerio; Chiara Mozzini; Ulisse Garbin; Giorgia Zambon; Luciano Cominacini
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-07-28

6.  An Interleukin 13 Polymorphism Is Associated with Symptom Severity in Adult Subjects with Ever Asthma.

Authors:  Simone Accordini; Lucia Calciano; Cristina Bombieri; Giovanni Malerba; Francesca Belpinati; Anna Rita Lo Presti; Alessandro Baldan; Marcello Ferrari; Luigi Perbellini; Roberto de Marco
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

7.  Assessment of asthma severity in adults with ever asthma: A continuous score.

Authors:  Lucia Calciano; Angelo Guido Corsico; Pietro Pirina; Giulia Trucco; Deborah Jarvis; Christer Janson; Simone Accordini
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

8.  Diverging trends of chronic bronchitis and smoking habits between 1998 and 2010.

Authors:  Simone Accordini; Angelo Guido Corsico; Isa Cerveri; Leonardo Antonicelli; Francesco Attena; Roberto Bono; Lucio Casali; Marcello Ferrari; Alessandro Fois; Pierpaolo Marchetti; Pietro Pirina; Roberta Tassinari; Giuseppe Verlato; Roberto de Marco
Journal:  Respir Res       Date:  2013-02-08

9.  The gender, age and risk factor distribution differs in self-reported allergic and non-allergic rhinitis: a cross-sectional population-based study.

Authors:  Lucia Cazzoletti; Marcello Ferrari; Mario Olivieri; Giuseppe Verlato; Leonardo Antonicelli; Roberto Bono; Lucio Casali; Isa Cerveri; Pierpaolo Marchetti; Pietro Pirina; Andrea Rossi; Simona Villani; Roberto de Marco
Journal:  Allergy Asthma Clin Immunol       Date:  2015-12-04       Impact factor: 3.406

10.  The course of asthma during pregnancy in a recent, multicase-control study on respiratory health.

Authors:  A Grosso; F Locatelli; E Gini; F Albicini; C Tirelli; I Cerveri; A G Corsico
Journal:  Allergy Asthma Clin Immunol       Date:  2018-04-17       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.